Advertisement

Topics

Week in Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue to Expand? News on Three China Life Science IPOs

08:49 EDT 12 May 2019 | ChinaBio Today

Industry Insights

• A deeply researched Wall Street Journal article describes Dr. Jiankui He, the man who used Crispr-Cas9 gene editing to alter human embryos in eight women from China, as a"product of his environment," not a rogue scientist working alone;
• Regulatory changes are speeding drug development timelines for novel imported drugs in China, and VCs raised over $40 billion in new funding last year. Was 2018 as good as it gets, or can the growth in investment activity continue?

Deals and Financings

• Beijing InnoCare Pharma is planning a Hong Kong IPO that could raise as much as $250 million at a $800 million valuation;
• Viva Biotech, a Shanghai CRO, raised $194 million in its Hong Kong IPO, and then traded 14% higher;
• Junshi Biosciences filed to IPO on Shanghai's new Technology Exchange, five months after completing a $394 million Hong Kong IPO;
• Zai Lab closed a $200 million follow-on financing, just eight months after its previous $150 million follow-on, as it nears launch for two candidates;
• Ally Bridge Group of Hong Kong led an over-subscribed $65 million financing of Pulmonx, a Bay Area pulmonary device maker;
• GeneQuantum of Suzhou closed a nearly $15 million Pre-B financing, led by Huagai Capital for clinical trials of its next-gen ADC candidates and new technologies;
• TAKE2 Health, a Hong Kong healthcare startup, in-licensed global rights to IP for an early nasopharyngeal cancer test from Grail, a diagnostics company;
• WuXi AppTec, China's largest CRO/CMO, acquired San Diego's Pharmapace, a CRO offering biometrics services for clinical trials;
• Harbour BioMed will partner with Chia Tai Tianqing, a Lianyungang pharma, to discover and develop next-gen biologics for targets in oncology and immunology;

Trials and Approvals

• Innovative Cellular Therapeutics, a US-Shanghai biotech, presented data from an ongoing clinical trial and preclinical studies of its novel CD19 CAR-T candidate;
• Connect Biopharma of Suzhou completed a successful Phase I ascending dose trial of its novel IL-4Rα antibody, CBP-201 for atopic dermatitis and other inflammatory diseases.

Stock Symbols: (HK: 1873) (HK: 1877; NEEQ: 833330) (NSDQ: ZLAB) (SHA: 603259; HK: 2359)

Share this with colleagues:

Original Article: Week in Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue to Expand? News on Three China Life Science IPOs

NEXT ARTICLE

More From BioPortfolio on "Week in Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue to Expand? News on Three China Life Science IPOs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...